{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:46:49Z","timestamp":1764701209920,"version":"3.40.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic disease that can progress to cirrhosis and liver failure. The natural history of PSC is variable as liver enzymes and liver symptoms fluctuate over time. Several drugs for PSC are under investigation, but there are currently no economic models to evaluate the cost-effectiveness and value of new treatments. The objective of this study was to develop an early economic model for PSC and validate the natural history component.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A lifetime horizon Markov cohort model was developed to track the progression of adults with PSC with or without inflammatory bowel disease. Based on relevant literature and clinical expert advice, fibrosis staging was used to model disease progression. Evidence on disease progression, mortality, PSC-related complications, and secondary cancers was identified by literature searches and validated by interviews with clinical and cost-effectiveness modelling experts. Model outcomes were overall survival and transplant-free survival years, and the proportions of patients receiving liver transplants, 2nd liver transplants after recurrent PSC (rPSC), and developing rPSC after liver transplantation during their lifetime. Cumulative incidence of secondary cancers and quality-adjusted life-years (QALYs) were also tracked.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Model outcomes are in line with estimates reported in literature recommended by clinical experts. Overall survival (95% uncertainty interval [UI]) was estimated to be 25.0 (23.2\u201326.3) years and transplant-free survival was estimated to be 22.0 (20.2\u201323.6) years. The estimated proportion (95% UI) of patients receiving first liver transplants was 14.5% (11.6\u201317.1%), while the proportion of patients developing rPSC and receiving 2nd liver transplants after rPSC was 24.2% (20.4\u201328.0%) and 21.6% (12.9\u201329.7%), respectively. The cumulative incidence (95% UI) of cholangiocarcinoma, colorectal cancer, and gallbladder cancer were estimated at 5.2% (2.1\u201310.0%), 3.6% (1.4\u20135.4%), and 3.3% (1.2\u20137.6%), respectively. Discounted lifetime QALYs per patient (95% UI) were estimated at 16.4 (15.6\u201317.1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We have developed a model framework to simulate the progression of PSC with estimates of overall and transplant-free survival. This model, which calibrates well with existing estimates of disease progression, may be useful to evaluate the clinical and economic benefits of future treatments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03658-8","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T18:23:36Z","timestamp":1742322216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of the natural history component of an early economic model for primary sclerosing cholangitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Christopher","family":"Bowlus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-0723","authenticated-orcid":false,"given":"Nandita","family":"Kachru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Rodriguez-Guadarrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ollendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"3658_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356\u201378.","journal-title":"Gut"},{"key":"3658_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","volume":"55","author":"N Barner-Rasmussen","year":"2020","unstructured":"Barner-Rasmussen N, Pukkala E, Jussila A, F\u00e4rkkil\u00e4 M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55:74\u201381.","journal-title":"Scand J Gastroenterol"},{"key":"3658_CR3","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/ijerph17093095","volume":"17","author":"M Carbone","year":"2020","unstructured":"Carbone M, Kodra Y, Rocchetti A, Manno V, Minelli G, Gerussi A, et al. Primary sclerosing cholangitis: burden of disease and mortality using data from the National Rare Diseases Registry in Italy. Int J Environ Res Public Health. 2020;17:3095.","journal-title":"Int J Environ Res Public Health"},{"key":"3658_CR4","doi-asserted-by":"publisher","first-page":"e7116","DOI":"10.1097\/MD.0000000000007116","volume":"96","author":"H Liang","year":"2017","unstructured":"Liang H, Manne S, Shick J, Lissoos T, Dolin P. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Med (Baltim). 2017;96:e7116.","journal-title":"Med (Baltim)"},{"key":"3658_CR5","doi-asserted-by":"crossref","unstructured":"Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C, Epidemiology. Natural history, and outcomes of primary sclerosing cholangitis: A systematic review of population-based studies. Clin Gastroenterol Hepatol. 2022;20:1687\u2013\u2009700.e4.","DOI":"10.1016\/j.cgh.2021.08.039"},{"key":"3658_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1750-1172-1-41","volume":"1","author":"J Worthington","year":"2006","unstructured":"Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis. 2006;1:41.","journal-title":"Orphanet J Rare Dis"},{"key":"3658_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00535-020-01663-1","volume":"55","author":"Z Bakhshi","year":"2020","unstructured":"Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, et al. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. J Gastroenterol. 2020;55:523\u201332.","journal-title":"J Gastroenterol"},{"key":"3658_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/MIB.0000000000000690","volume":"22","author":"R Jegadeesan","year":"2016","unstructured":"Jegadeesan R, Navaneethan U, Bharadwaj S, Hammel J, Sanaka MR, Shen B. Impact of concurrent Non-IBD immunological diseases on the outcome of primary sclerosing cholangitis. Inflamm Bowel Dis. 2016;22:948\u201354.","journal-title":"Inflamm Bowel Dis"},{"key":"3658_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3748\/wjg.v25.i6.659","volume":"25","author":"BM Fung","year":"2019","unstructured":"Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019;25:659\u201371.","journal-title":"World J Gastroenterol"},{"key":"3658_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646\u201359. quiz 60.","journal-title":"Am J Gastroenterol"},{"key":"3658_CR11","doi-asserted-by":"publisher","first-page":"10646","DOI":"10.1038\/s41598-021-90175-w","volume":"11","author":"D Aune","year":"2021","unstructured":"Aune D, Sen A, Norat T, Riboli E, Folseraas T. Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Sci Rep. 2021;11:10646.","journal-title":"Sci Rep"},{"key":"3658_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cld.633","volume":"9","author":"RW Chapman","year":"2017","unstructured":"Chapman RW. Update on primary sclerosing cholangitis. Clin Liver Dis (Hoboken). 2017;9:107\u201310.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"3658_CR13","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045\u201355.","journal-title":"Hepatology"},{"key":"3658_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298\u2013323.","journal-title":"J Hepatol"},{"key":"3658_CR15","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:2501\u20132.","journal-title":"N Engl J Med"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2017.06.027","volume":"67","author":"PJ Trivedi","year":"2017","unstructured":"Trivedi PJ, Scalera I, Slaney E, Laing RW, Gunson B, Hirschfield GM, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. J Hepatol. 2017;67:957\u201365.","journal-title":"J Hepatol"},{"key":"3658_CR17","doi-asserted-by":"publisher","first-page":"S902","DOI":"10.14309\/00000434-201510001-02168","volume":"110","author":"MA Mouchli","year":"2015","unstructured":"Mouchli MA, Singh S, Talwalkar JA, Watt K, Poterucha JJ, Loftus EVJ, et al. Rate, risk factors, and outcomes of recurrence of primary sclerosing cholangitis after liver transplantation: 2168. Am J Gastroenterol. 2015;110:S902.","journal-title":"Am J Gastroenterol"},{"key":"3658_CR18","unstructured":"2020\u20132023 Value Assessment Framework [Internet]. 2020 [cited 2023 October 12]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_2020_2023_VAF_013120-4-2.pdf"},{"key":"3658_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.14309\/ajg.0000000000000268","volume":"114","author":"RT Yokoda","year":"2019","unstructured":"Yokoda RT, Carey EJ. Primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114:1593\u2013605.","journal-title":"Am J Gastroenterol"},{"key":"3658_CR20","unstructured":"NICE appraisal - Obeticholic acid for treatment primary biliary cholangitis [ID785]. [Internet]. NICE. 2017 [cited 2022 November 21]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta443\/documents\/committee-papers"},{"key":"3658_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","volume":"19","author":"KP Batts","year":"1995","unstructured":"Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409\u201317.","journal-title":"Am J Surg Pathol"},{"key":"3658_CR22","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/S0618-8278(19)30018-0","volume":"70","author":"C Bowlus","year":"2019","unstructured":"Bowlus C, Shiffman M, Janssen H, Montano-Loza AJ, Caldwell S, Luketic V, et al. Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis. J Hepatol. 2019;70:e10\u20131.","journal-title":"J Hepatol"},{"key":"3658_CR23","unstructured":"Vancomycin for primary sclerosing cholangitis. [Internet]. 2022 [cited 2022 December 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710122"},{"key":"3658_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","volume":"73","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73:94\u2013101.","journal-title":"J Hepatol"},{"key":"3658_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, et al. The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788\u2013801.","journal-title":"Hepatology"},{"key":"3658_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1619","volume":"5","author":"B Eksteen","year":"2021","unstructured":"Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, Fischer L, Vig P, et al. Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study. Hepatol Commun. 2021;5:478\u201390.","journal-title":"Hepatol Commun"},{"key":"3658_CR27","unstructured":"Safety, tolerability, and efficacy of cilofexor in non-cirrhotic adults with primary sclerosing cholangitis (PRIMIS) [Internet]. 2022 [cited 2022 December 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03890120"},{"key":"3658_CR28","doi-asserted-by":"crossref","unstructured":"Wright M, Grieve R, Roberts J, Main J, Thomas HC, Investigators UKMHCT. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1-113, iii.","DOI":"10.3310\/hta10210"},{"key":"3658_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause- specific mortality in patients with advanced nonalcoholic fatty liver disease: A multi- national cohort study. Gastroenterology. 2018;155:443\u201357. e17.","journal-title":"Gastroenterology"},{"key":"3658_CR30","doi-asserted-by":"publisher","first-page":"e2015756","DOI":"10.1001\/jamanetworkopen.2020.15756","volume":"3","author":"M Tatar","year":"2020","unstructured":"Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States. JAMA Netw Open. 2020;3:e2015756.","journal-title":"JAMA Netw Open"},{"key":"3658_CR31","doi-asserted-by":"publisher","first-page":"S511","DOI":"10.14309\/00000434-201710001-00915","volume":"112","author":"OY Mousa","year":"2017","unstructured":"Mousa OY, Patel NJ, Pang M, Nimri SM, Harnois D. Survival outcomes of liver transplant patients with primary sclerosing cholangitis and inflammatory bowel disease: 914. Am J Gastroenterol. 2017;112:S511\u20133.","journal-title":"Am J Gastroenterol"},{"key":"3658_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","volume":"53","author":"L Lindstrom","year":"2018","unstructured":"Lindstrom L, Jorgensen KK, Boberg KM, Castedal M, Rasmussen A, Rostved AA, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic multicentre study. Scand J Gastroenterol. 2018;53:297\u2013304.","journal-title":"Scand J Gastroenterol"},{"key":"3658_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0168-8278(97)80356-X","volume":"27","author":"DM Harnois","year":"1997","unstructured":"Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 1997;27:512\u20136.","journal-title":"J Hepatol"},{"key":"3658_CR34","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","volume":"27","author":"C Kulkarni","year":"2020","unstructured":"Kulkarni C, Murag S, Cholankeril G, Fardeen T, Mannalithara A, Lerrigo R, et al. Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2020;27:1602\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"3658_CR35","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/hep.24570","volume":"54","author":"N Razumilava","year":"2011","unstructured":"Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842\u201352.","journal-title":"Hepatology"},{"key":"3658_CR36","doi-asserted-by":"publisher","first-page":"S919","DOI":"10.1016\/S0016-5085(16)33116-X","volume":"150","author":"M Bolliet","year":"2016","unstructured":"Bolliet M, Besch C, Nguimpi-Tambou M, Addeo P, Bachellier P, Duclos B, et al. Cholangiocarcinoma and colorectal cancer in patients with primary sclerosing cholangitis and\/or inflammatory bowel disease: A retrospective study (1985\u20132014). Gastroenterology. 2016;150:S919.","journal-title":"Gastroenterology"},{"key":"3658_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","volume":"63","author":"R Ravikumar","year":"2015","unstructured":"Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63:1139\u201346.","journal-title":"J Hepatol"},{"key":"3658_CR38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apt.12435","volume":"38","author":"KM Boberg","year":"2013","unstructured":"Boberg KM, Wisl\u00f8ff T, Kj\u00f8llesdal KS, St\u00f8vring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther. 2013;38:794\u2013803.","journal-title":"Aliment Pharmacol Ther"},{"key":"3658_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.28932","volume":"65","author":"S Samur","year":"2017","unstructured":"Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017;65:920\u20138.","journal-title":"Hepatology"},{"key":"3658_CR40","unstructured":"Pearson SD, Banken R, Chapman R, Emond SK, Loos AM, Russo ET et al. Obeticholic acid for the treatment of primary biliary cholangitis: Comparative clinical effectiveness, value, and value-based price benchmarks. [Internet]. Institute for Clinical and Economic Review; 2016 [cited 2022 December 1]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/NECEPAC_OCA_PBC_Evidence_Report_062316.pdf"},{"key":"3658_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"3658_CR42","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s00261-021-03269-4","volume":"47","author":"A Ozturk","year":"2022","unstructured":"Ozturk A, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY). 2022;47:3037\u201350.","journal-title":"Abdom Radiol (NY)"},{"key":"3658_CR43","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s00261-021-03396-y","volume":"47","author":"SK Venkatesh","year":"2022","unstructured":"Venkatesh SK, Torbenson MS. Liver fibrosis quantification. Abdom Radiol (NY). 2022;47:1032\u201352.","journal-title":"Abdom Radiol (NY)"},{"key":"3658_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s11605-009-0898-3","volume":"13","author":"R Kashyap","year":"2009","unstructured":"Kashyap R, Mantry P, Sharma R, Maloo MK, Safadjou S, Qi Y, et al. Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis. J Gastrointest Surg. 2009;13:1480\u20136.","journal-title":"J Gastrointest Surg"},{"key":"3658_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11136-015-1161-x","volume":"25","author":"E Kalaitzakis","year":"2016","unstructured":"Kalaitzakis E, Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, et al. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Qual Life Res. 2016;25:947\u201357.","journal-title":"Qual Life Res"},{"key":"3658_CR46","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/1471-2407-12-390","volume":"12","author":"A Zabernigg","year":"2012","unstructured":"Zabernigg A, Giesinger JM, Pall G, Gamper EM, Gattringer K, Wintner LM, et al. Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer. 2012;12:390.","journal-title":"BMC Cancer"},{"key":"3658_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0272989X14536779","volume":"34","author":"S Djalalov","year":"2014","unstructured":"Djalalov S, Rabeneck L, Tomlinson G, Bremner KE, Hilsden R, Hoch JS. A review and meta-analysis of colorectal cancer utilities. Med Decis Mak. 2014;34:809\u201318.","journal-title":"Med Decis Mak"},{"key":"3658_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1017\/S0266462306050902","volume":"22","author":"K Howard","year":"2006","unstructured":"Howard K, Lord SJ, Speer A, Gibson RN, Padbury R, Kearney B. Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies. Int J Technol Assess Health Care. 2006;22:109\u201318.","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03658-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T18:57:09Z","timestamp":1742324229000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03658-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03658-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB has received grant funding and advisor fees from CymaBay Therapeutics, GSK, and Ipsen Bioscience; and has received grant funding from Boston Scientific, Calliditas Therapeutics, Cara Therapeutics, Chemomab, COUR Pharmaceuticals, Gilead Sciences, Hanmi Pharmaceuticals, Intercept Pharmaceuticals, Mirum Pharmaceuticals, Novo Nordisk, Pliant Therapeutics, and Viking Therapeutics; and has received advisor fees from Invea Therapeutics. CL has received grant funding and consultant fees from Calliditas Therapeutics, CymaBay Therapeutics, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen Bioscience, and Pliant Therapeutics; and has received grant funding from Cara Therapeutics, Escient Pharmaceuticals, GENFIT, HighTide Therapeutics, Mirum Pharmaceuticals, Novartis, and Zydus Lifesciences. KVK has received grant funding and consultant fees from CymaBay Therapeutics, GENFIT, Gilead Sciences, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Mirum Pharmaceuticals, NGM Biopharmaceuticals, Pfizer, and 89Bio; has received consultant fees from Enanta Pharmaceuticals, HighTide Therapeutics, and Inipharm; has received grant funding from Corcept Therapeutics, GSK, Hanmi Pharmaceutical, Novo Nordisk, Pliant Therapeutics, Terns Pharmaceuticals, and Viking Therapeutics; has received speaker bureau honoraria from AbbVie, Gilead Sciences, and Intercept Pharmaceuticals; and has stock options with Inipharm. NK is an employee of, and has stock options with, Gilead Sciences. SJ, YR, and NS are employees of Maple Health Group who conducted\/executed the study on behalf of Gilead Sciences and were paid by Gilead Sciences for their services. AB and MS have received consultant fees from Gilead Sciences. DO has received consultant fees from Gilead Sciences and is employed at a research center that accepts sponsorship funding for its databases from life sciences companies, government agencies, and academic institutions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}